"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 5 | 7 |
| 1996 | 2 | 3 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 3 | 4 | 7 |
| 1999 | 4 | 2 | 6 |
| 2000 | 1 | 8 | 9 |
| 2001 | 6 | 2 | 8 |
| 2002 | 5 | 6 | 11 |
| 2003 | 8 | 6 | 14 |
| 2004 | 8 | 5 | 13 |
| 2005 | 10 | 6 | 16 |
| 2006 | 5 | 9 | 14 |
| 2007 | 9 | 4 | 13 |
| 2008 | 7 | 1 | 8 |
| 2009 | 9 | 8 | 17 |
| 2010 | 9 | 4 | 13 |
| 2011 | 9 | 8 | 17 |
| 2012 | 10 | 6 | 16 |
| 2013 | 9 | 5 | 14 |
| 2014 | 15 | 2 | 17 |
| 2015 | 21 | 5 | 26 |
| 2016 | 10 | 13 | 23 |
| 2017 | 24 | 8 | 32 |
| 2018 | 20 | 7 | 27 |
| 2019 | 15 | 8 | 23 |
| 2020 | 18 | 13 | 31 |
| 2021 | 19 | 13 | 32 |
| 2022 | 4 | 31 | 35 |
| 2023 | 4 | 20 | 24 |
| 2024 | 8 | 7 | 15 |
| 2025 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
-
Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro. J Infect Dis. 2025 Feb 04; 231(1):e68-e76.
-
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
-
AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 2025 Feb; 168(2):267-284.
-
Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors. J Virol. 2025 Feb 25; 99(2):e0175724.
-
New insights into gold nanoparticles in virology: A review of their applications in the prevention, detection, and treatment of viral infections. Biomed Pharmacother. 2025 Feb; 183:117844.
-
2'-Fucosyllactose inhibits human norovirus replication in human intestinal enteroids. J Virol. 2025 Feb 25; 99(2):e0093824.
-
Hepatitis B Virus Treatment in Children: Common Challenges and Management Options in a Case-Based Format. J Pediatric Infect Dis Soc. 2024 Nov 21; 13(Supplement_5):S142-S147.
-
Underutilization of Influenza Antiviral Treatment Among Children and Adolescents at Higher Risk for Influenza-Associated Complications - United States, 2023-2024. MMWR Morb Mortal Wkly Rep. 2024 Nov 14; 73(45):1022-1029.
-
COVID-19 vaccination modified the effect of nirmatrelvir-ritonavir on post-acute mortality and rehospitalization: a retrospective cohort study. Emerg Microbes Infect. 2024 Dec; 13(1):2421397.